Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
inosine pranobex
- Development stage
- Phase 4
- Lead developer
- Mochida Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Inosine pranobex (also known as inosine acedoben dimepranol or methisoprinol) is a synthetic compound that combines inosine with dimepranol acedoben (a salt of p-acetamidobenzoic acid and N,N-dimethylamino-2-propanol) in a 1:3 molar ratio. It functions as both an immunomodulator and an antiviral agent. Its primary mechanism involves stimulating the cell-mediated immune response, specifically by enhancing T-lymphocyte differentiation and proliferation, increasing natural killer (NK) cell activity, and promoting the production of pro-inflammatory cytokines such as interleukin-1 (IL-1), interleukin-2 (IL-2), and interferon-gamma (IFN-γ). Additionally, it exerts antiviral effects by inhibiting viral RNA synthesis and translation. Originally developed by Newport Pharmaceuticals, it has been extensively studied for conditions like AIDS-related complex (ARC), though it is currently most commonly used for subacute sclerosing panencephalitis (SSPE), herpes simplex, and various viral respiratory infections.
- Brand names
- IsoprinosineImunovirDelimmunViruxanGroprinosinInosiplex
- Other names
- Inosine acedoben dimepranolMethisoprinolInosine:dimepranol acedoben 1:3
02
Targets
vRNA (Coronavirus viral RNA)
Beyond the preview
Go deeper on inosine pranobex.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on inosine pranobex.